Nomic and Broad Clinical Labs to build proteomics platform 

Biotechnology company Nomic Bio has announced a partnership with Broad Clinical Labs (BCL) to build a scalable proteomics platform. 

The organisations will look to integrate Nomic’s Omni 1000 solution into BCL’s existing capabilities to develop new application-specific solutions.  

Based on nELISA technology, Nomic says Omni 1000 measures over 1,050 biologically relevant proteins with absolute quantification, enabling generation of interoperable proteomic data at the scale and consistency required for translational studies, clinical programmes, and large multi-omic research efforts.  

The partnership aims to support applications where quantitative, large-scale proteomic data can expand existing workflows. This includes precision oncology, end-to-end biomarker and clinical trial workflows and multi-omics studies designed to generate interoperable datasets for disease research and precision medicine. 

Initial development of the platform is underway, with plans to offer jointly developed solutions starting in early 2027. 

“We’re thrilled to be working with BCL because they are exactly the kind of organisation that can help embed our transformative technology into important research and clinical workflows,” said Milad Dagher, CEO of Nomic.  

“This collaboration reflects our focus on building a quantitative, scalable proteomics platform that integrates naturally into the workflows that matter most.” 

“Our mission is to enable data generation and integrated workflows that move discovery and translational research forward,” added Niall Lennon, Chair and Chief Scientific Officer at Broad Clinical Laboratories.  

“One of the longstanding challenges has been making proteomic data as scalable, usable, and comparable as other core modalities. Nomic brings an approach that helps address that need, and we’re excited about what this will enable across research, biomarker development, and clinical applications.” 

The post Nomic and Broad Clinical Labs to build proteomics platform  appeared first on Drug Discovery World (DDW).